Moreover, the specific HER2, JNK and ERKs inhibition, the anti-angiogenic and anti-migration activity together with the in vivo anti-tumor and anti-metastatic effect and the non-systemic toxicity of Bozepinib, encourage further studies on the therapeutic potential of this novel synthetic compound in breast and colon cancer patients. This evidence concerns the gene ERBB2 and colonic neoplasm.